期刊文献+

距离比较法构建表皮生长因子受体抑制剂的药效团模型 被引量:2

Using Distance Comparison Method to Build Pharmacophore Model of Epidermal Growth Factor Receptor Inhibitors
在线阅读 下载PDF
导出
摘要 目的 构建表皮生长因子受体(EGFR)抑制剂的药效团模型,设计新结构类型的化合物。方法 在EGFR结构的诱导下得到抑制剂活性构象集,将13个不同结构特征的EGFR抑制剂的构象进行叠合,应用距离比较法建立合理的药效团模型;初步验证模型的有效性,对数据库进行基于三维药效团模型的搜索和分子对接。结果 得到了EGFR抑制剂的三维药效团模型,根据此模型设计了新结构类型的化合物。结论 基于三维药效团模型进行药物分子的设计,可以减少后续工作的计算量,提高先导化合物的命中率,用于指导新型的酪氨酸激酶抑制剂的设计。 Objective To build 3D-pharmacophore model of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors using distance comparisons method and design novel EGFR inhibitors. Methods Thirteen typical EGFR inhibitors were selected, and their biologically active conformations were obtained by using DOCK5.0 program, then 3D-pharmacophore model of EGFR inhibitors was built using distance comparisons method. Results Validation of the 3D-pharmacophore model was carried out and novel structures with potential inhibitory activity were selected by means of 3D-searching and docking method. Conclusion This method can improve hit rate of lead compounds discovery and can be used to design novel EGFR inhibitors.
出处 《中国医学科学院学报》 CAS CSCD 北大核心 2004年第4期379-384,共6页 Acta Academiae Medicinae Sinicae
基金 国家自然科学基金(20072057)资助~~
关键词 距离比较法 表皮生长因子 受体抑制剂 药效团模型 EGFR 构象 distance comparisons epidermal growth factor receptor pharmacophore model
  • 相关文献

参考文献15

  • 1Fry DW. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors.Pharmacol Ther, 1999, 82:207-218
  • 2Khazaie K, Schirrmacher V, Lichtner RB. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev, 1993, 12:255 -274
  • 3Wakeling AE, Barker A J, Davies DH, et al. New targets for therapeutic attack. Endocr Relat Cancer, 1997, 4:351-355
  • 4Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs, 2000, 59(4):753-767
  • 5Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem,2002, 277(48):46265-46272
  • 6Wissner A, Berger DM, Boschelli DH, et al. 4-anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialk- oxyquinazoline inhibitors. J Med Chem,2000, 43(
  • 7Singh J, Dobrusin EM, Fry DW, et al. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases. J Med Chem, 1997, 40(7):1130-1135
  • 8Drug Data Report. Prous JR. 2002, 24. Danvers: Prous Science, 2002
  • 9Wissner A, Overbeek E, Reich MF, et al. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth
  • 10Drug Data Report. Prous JR. 2001, 23. Danvers: Prous Science, 2002

二级参考文献14

  • 1Pong, S. S. ; Levine, L. J. Pharmacol. Exp. Ther. 1976,196, 226.
  • 2Allison, M. C. ; Howatson, A. G. ; Torrance, C. N. Engl. J.Med. 1992, 327, 749.
  • 3Fletcher, B. S. ; Kujubu, D. A. ; Perrin, D. M. ; Herschman,H. R. J. Biol. Chem. 1992, 267, 4338.
  • 4Kujubu, D. A. ; Fletcher, B. S. ; Vamum, B. C. J. Biol.Chem. 1991, 266(20), 12866.
  • 5The program sybyl 6.5 is availahle from Tripos Assoc., 1699 S.Hanley Rd., St. louis, MO 63144, 1998.
  • 6Puig, C.; Crespo, M. I.; Godessart, N. J. Med. Chem.2000, 43(2), 214.
  • 7Black, W. C. ; Brideau, C. ; Chan, C. C. J. Med. Chem.1999, 42(7), 1274.
  • 8Li, C. S. ; Black, W. C. ; Brideau, C. Bioorg. Med. Chem.Lett. 1999, 9(22), 3181.
  • 9Lau, C. K. ; Brideau, C. ; Chan, C. C. Bioorg. Med. Chem.Lett. 1999, 9(22), 3187.
  • 10Lei, X. S.; Zhu, Q. Q.; Qu, L. B.; Guo, Z. R. Acta Pharm.Sinica 1999, 34,590 (in Chinese).

共引文献1

同被引文献27

  • 1牛彦,裴剑锋,吕雯,雷小平.距离比较法构建M_1受体激动剂药效团模型[J].化学学报,2005,63(22):2021-2026. 被引量:3
  • 2Martin YC, Burse MG, Dahaner EA, et al. A fast approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists. Computer-Aided Molecular Design, 1993, (7): 83.
  • 3Dhilon S. Patel,Prasad V. Bharatam. New leads for selective GSK-3 inhibition: pharmacophore mapping and virtual screening studies. Computer-Aided Molecular Design, 2006, (20): 55-66.
  • 4O. Nicolotti, M. Pellegrini-Calace, A. Carrieri, et al. Neuronal nicotinic receptor agonists: a multi-approach development of the pharmacophore. Computer-Aided Molecular Design, 2001, (15): 859-872.
  • 5Eva.S., Istvan, Deisenhofer. Structural mechanism for statin inhibition of HMG-CoA reductase . Science, 2001, (292): 1160-1170.
  • 6G.A.Holdgate, W.H.J. Ward,F. Mc Taggart. Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochemical Society Transactions, 2003, 31 (3): 528-531.
  • 7Qing Y, Zhang JianWan, XinXu, et al. Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening. Combinational Chemistry, 2007, 9 (1): 131-138.
  • 8Pidgeon C, Ong S, Liu H, et al. IAM ehromatography: in vitro screen for predicting drug membrane permeabilily [J]. J Med Chem, 1995,38:590-594.
  • 9Marrink SJ, Jahnig F, Bereodsen H J, et al. Proton transport across transient single-file water pores in a lipid membrane studied by molecular dynamics simulations [ J ]. Biophys J, 1996,71:632 -647.
  • 10Oprea T, Davis AM, Teaque SJ, el al. Is there a difference between leads and drugs? [J]. J Chem Inf Comput Sci, 2001,41:1308 - 1315.

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部